Breaking Canadian GLP-1 news
GLP-1 News — Page 10
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Where are you in your GLP-1 journey?
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
India Launches Generic Semaglutide at $14 Monthly This Weekend
India becomes first major market to launch generic semaglutide at $14 monthly, with 50 brands expected as Canada awaits Health Canada approvals for nine applications.
Generic Semaglutide Could Cost Just $15 Monthly Worldwide
New reports indicate generic semaglutide could be priced as low as $15 monthly or $3 per dose globally, significantly undercutting current brand prices.
Novo Nordisk Considers Renamed Ozempic to Fight Generics
Novo Nordisk explores launching a lower-priced, renamed version of Ozempic in Canada as nine generic semaglutide applications undergo Health Canada review.
Health Canada Approves Heart Protection for Rybelsus Pill
Health Canada approves new cardiovascular indication for Rybelsus semaglutide pill, making it first oral GLP-1 with heart protection approval in Canada.
PharmaTher Joins Generic Semaglutide Race in Canada
PharmaTher launches strategic initiative to pursue Health Canada approval for generic semaglutide as regulatory exclusivity ended in January 2026.
Provinces Await Health Canada Approval Before Generic Coverage
Most provinces tell insurers they're waiting on Health Canada approvals before deciding coverage policies for generic semaglutide medications.
Health Canada's 180-Day Generic Review Beats Global Timelines
Health Canada's 180-day generic drug review timeline is shorter than similar regulatory agencies worldwide, potentially accelerating generic GLP-1 approvals.
Public Plans Should Cover Generic GLP-1s, Expert Says
Healthcare expert recommends public insurance plans cover generic semaglutide when available, citing accessibility benefits. Latest from GLP1Prices.ca
Novo Nordisk Cuts Wegovy Cash Price to $349 Monthly in Canada
Novo Nordisk announces new $349 monthly cash price for Wegovy in Canada, representing significant reduction from previous pricing - GLP1Prices.ca
Health Canada Issues Counterfeit GLP-1 Drug Warning
Health Canada warns Canadians about fake semaglutide and tirzepatide products as demand grows. Get the latest on GLP1Prices.ca
Health Canada Sets 180-Day Review Timeline for Generic GLP-1s
Health Canada confirms 180-day target timeline for reviewing nine generic semaglutide applications currently under regulatory assessment. GLP1Prices.ca
Retatrutide Triple Agonist Drug Enters Phase 3 Trials in Canada
Health Canada has not yet approved retatrutide, but the experimental triple agonist GLP-1 medication is advancing through clinical trials - GLP1Prices.ca
Health Canada Issues Notice of Compliance for New Wegovy Indication
Health Canada granted Notice of Compliance under NOC/c policy for new Wegovy indication in January 2026. Latest regulatory updates at GLP1Prices.ca
Vimy Pharma Plans Canadian-Made Generic Semaglutide Filing
Vimy Pharma expects to file generic semaglutide application with Health Canada in coming weeks, joining nine other companies. Latest on GLP1Prices.ca
FDA Approves Oral Wegovy 25mg as First Weight Management Pill
FDA approved Novo Nordisk's oral Wegovy 25mg in December 2025 as first oral GLP-1 for weight management. Canadian approval timeline at GLP1Prices.ca
Generic Semaglutide to Test Canadian Employer Drug Budgets
Canadian employers face drug plan budget pressures as generic semaglutide launches mid-2026 with expected 65% price cuts. Coverage at GLP1Prices.ca
Alberta Blue Cross Delays Generic Semaglutide Launch to Mid-2026
Alberta Blue Cross reports generic semaglutide launch delayed until mid-2026, affecting employer drug plan cost relief expectations. Track updates at GLP1Prices.ca
Health Canada Tracker Shows 9 Generic Semaglutide Reviews
Health Canada's new public tracker reveals status of nine generic semaglutide applications under review, providing transparency - GLP1Prices.ca
Lilly Finds Impurity in Compounded Tirzepatide Products 2026
Eli Lilly reports impurities in compounded versions of tirzepatide, raising safety concerns for Canadian patients using non-authorized products. GLP1Prices.ca
Canada's Drug Agency to Decide Mounjaro Public Coverage
Provincial health plans await recommendation on Mounjaro coverage as assessment nears completion. Latest updates at GLP1Prices.ca
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada